Stay updated with breaking news from Trial Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine Dupixent is the first and only investigational biologic
Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine Dupixent...
Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo Dupixent is the... | May 21, 2023
FinancialContent fully hosted finance channel
FinancialContent fully hosted finance channel